APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mesenchymal Stem Cell Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mesenchymal Stem Cell Drugs Market Outlook and Growth Opportunities 2026

27 December 2025199 pages

Choose your research edition.

Industry ResearchMesenchymal Stem Cell Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mesenchymal Stem Cell Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Mesenchymal Stem Cell Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mesenchymal Stem Cell Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Mesenchymal Stem Cell Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Mesenchymal Stem Cell Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mesenchymal Stem Cell Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mesenchymal Stem Cell Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mesenchymal Stem Cell Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mesenchymal Stem Cell Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mesenchymal Stem Cell Drugs market include Anterogen, JCR Pharmaceuticals, Medipost, Pharmicell, Stempeutics, Osiris Therapeutics, CHIESI Farmaceutici and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mesenchymal Stem Cell Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mesenchymal Stem Cell Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mesenchymal Stem Cell Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mesenchymal Stem Cell Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Mesenchymal Stem Cell Drugs Segment by Company

Anterogen

JCR Pharmaceuticals

Medipost

Pharmicell

Stempeutics

Osiris Therapeutics

CHIESI Farmaceutici

Takeda

Mesenchymal Stem Cell Drugs Segment by Type

Autologous Source

Allogeneic Source

Mesenchymal Stem Cell Drugs Segment by Application

Tissue Repair

Immunomodulation

Mesenchymal Stem Cell Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mesenchymal Stem Cell Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mesenchymal Stem Cell Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mesenchymal Stem Cell Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Mesenchymal Stem Cell Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesenchymal Stem Cell Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mesenchymal Stem Cell Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesenchymal Stem Cell Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mesenchymal Stem Cell Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mesenchymal Stem Cell Drugs industry.

Chapter 3: Detailed analysis of Mesenchymal Stem Cell Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mesenchymal Stem Cell Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mesenchymal Stem Cell Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mesenchymal Stem Cell Drugs Industry Trends Table 2. Mesenchymal Stem Cell Drugs Industry Drivers Table 3. Mesenchymal Stem Cell Drugs Industry Opportunities and Challenges Table 4. Mesenchymal Stem Cell Drugs Industry Restraints Table 5. Global Mesenchymal Stem Cell Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mesenchymal Stem Cell Drugs Revenue Share by Company (2021-2026) Table 7. Global Mesenchymal Stem Cell Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Mesenchymal Stem Cell Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Mesenchymal Stem Cell Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mesenchymal Stem Cell Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Mesenchymal Stem Cell Drugs Company, Product Type & Application Table 13. Global Mesenchymal Stem Cell Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mesenchymal Stem Cell Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Autologous Source Table 18. Significant Companies of Allogeneic Source Table 19. Global Mesenchymal Stem Cell Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Mesenchymal Stem Cell Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Mesenchymal Stem Cell Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Mesenchymal Stem Cell Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Mesenchymal Stem Cell Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Mesenchymal Stem Cell Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Mesenchymal Stem Cell Drugs Sales Value Share by Type (2021-2026) Table 28. Global Mesenchymal Stem Cell Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Tissue Repair Table 30. Significant Companies of Immunomodulation Table 31. Global Mesenchymal Stem Cell Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Mesenchymal Stem Cell Drugs Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Mesenchymal Stem Cell Drugs Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Application (2021-2026) Table 35. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Application (2027-2032) Table 36. Global Mesenchymal Stem Cell Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Mesenchymal Stem Cell Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Mesenchymal Stem Cell Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Mesenchymal Stem Cell Drugs Sales Value Share by Application (2021-2026) Table 40. Global Mesenchymal Stem Cell Drugs Sales Value Share by Application (2027-2032) Table 41. Global Mesenchymal Stem Cell Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Mesenchymal Stem Cell Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Mesenchymal Stem Cell Drugs Sales Market Share by Region (2021-2026) Table 44. Global Mesenchymal Stem Cell Drugs Sales by Region (2027-2032) & (K Units) Table 45. Global Mesenchymal Stem Cell Drugs Sales Market Share by Region (2027-2032) Table 46. Global Mesenchymal Stem Cell Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Mesenchymal Stem Cell Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Mesenchymal Stem Cell Drugs Sales Value Share by Region (2021-2026) Table 49. Global Mesenchymal Stem Cell Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Mesenchymal Stem Cell Drugs Sales Value Share by Region (2027-2032) Table 51. Global Mesenchymal Stem Cell Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Mesenchymal Stem Cell Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Mesenchymal Stem Cell Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Mesenchymal Stem Cell Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Mesenchymal Stem Cell Drugs Sales by Country (2021-2026) & (K Units) Table 56. Global Mesenchymal Stem Cell Drugs Sales Market Share by Country (2021-2026) Table 57. Global Mesenchymal Stem Cell Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global Mesenchymal Stem Cell Drugs Sales Market Share by Country (2027-2032) Table 59. Global Mesenchymal Stem Cell Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Mesenchymal Stem Cell Drugs Sales Value Market Share by Country (2021-2026) Table 61. Global Mesenchymal Stem Cell Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Mesenchymal Stem Cell Drugs Sales Value Market Share by Country (2027-2032) Table 63. Anterogen Company Information Table 64. Anterogen Business Overview Table 65. Anterogen Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Anterogen Mesenchymal Stem Cell Drugs Product Portfolio Table 67. Anterogen Recent Development Table 68. JCR Pharmaceuticals Company Information Table 69. JCR Pharmaceuticals Business Overview Table 70. JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Product Portfolio Table 72. JCR Pharmaceuticals Recent Development Table 73. Medipost Company Information Table 74. Medipost Business Overview Table 75. Medipost Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Medipost Mesenchymal Stem Cell Drugs Product Portfolio Table 77. Medipost Recent Development Table 78. Pharmicell Company Information Table 79. Pharmicell Business Overview Table 80. Pharmicell Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pharmicell Mesenchymal Stem Cell Drugs Product Portfolio Table 82. Pharmicell Recent Development Table 83. Stempeutics Company Information Table 84. Stempeutics Business Overview Table 85. Stempeutics Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Stempeutics Mesenchymal Stem Cell Drugs Product Portfolio Table 87. Stempeutics Recent Development Table 88. Osiris Therapeutics Company Information Table 89. Osiris Therapeutics Business Overview Table 90. Osiris Therapeutics Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Osiris Therapeutics Mesenchymal Stem Cell Drugs Product Portfolio Table 92. Osiris Therapeutics Recent Development Table 93. CHIESI Farmaceutici Company Information Table 94. CHIESI Farmaceutici Business Overview Table 95. CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Product Portfolio Table 97. CHIESI Farmaceutici Recent Development Table 98. Takeda Company Information Table 99. Takeda Business Overview Table 100. Takeda Mesenchymal Stem Cell Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Takeda Mesenchymal Stem Cell Drugs Product Portfolio Table 102. Takeda Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Mesenchymal Stem Cell Drugs Distributors List Table 106. Mesenchymal Stem Cell Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Mesenchymal Stem Cell Drugs Product Image Figure 2. Global Mesenchymal Stem Cell Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mesenchymal Stem Cell Drugs Sales (2021-2032) & (K Units) Figure 5. Global Mesenchymal Stem Cell Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Mesenchymal Stem Cell Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Autologous Source Image Figure 10. Allogeneic Source Image Figure 11. Global Mesenchymal Stem Cell Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Mesenchymal Stem Cell Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Mesenchymal Stem Cell Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Mesenchymal Stem Cell Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Mesenchymal Stem Cell Drugs Sales Value Share by Type (2021-2032) Figure 17. Tissue Repair Image Figure 18. Immunomodulation Image Figure 19. Global Mesenchymal Stem Cell Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Mesenchymal Stem Cell Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Mesenchymal Stem Cell Drugs Sales Volume Share by Application (2021-2032) Figure 22. Global Mesenchymal Stem Cell Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Mesenchymal Stem Cell Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Mesenchymal Stem Cell Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Mesenchymal Stem Cell Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Mesenchymal Stem Cell Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Mesenchymal Stem Cell Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Mesenchymal Stem Cell Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. North America Mesenchymal Stem Cell Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Mesenchymal Stem Cell Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Mesenchymal Stem Cell Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. South America Mesenchymal Stem Cell Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Mesenchymal Stem Cell Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Mesenchymal Stem Cell Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Mesenchymal Stem Cell Drugs Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Mesenchymal Stem Cell Drugs Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Autologous Source
  • Allogeneic Source
Applications
  • Tissue Repair
  • Immunomodulation
Companies covered
  • Anterogen
  • JCR Pharmaceuticals
  • Medipost
  • Pharmicell
  • Stempeutics
  • Osiris Therapeutics
  • CHIESI Farmaceutici
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Mesenchymal Stem Cell Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Mesenchymal Stem Cell Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mesenchymal Stem Cell Drugs Market Dynamics
  1. 2.1 Mesenchymal Stem Cell Drugs Industry Trends
  2. 2.2 Mesenchymal Stem Cell Drugs Industry Drivers
  3. 2.3 Mesenchymal Stem Cell Drugs Industry Opportunities and Challenges
  4. 2.4 Mesenchymal Stem Cell Drugs Industry Restraints
3 Mesenchymal Stem Cell Drugs Market by Company
  1. 3.1 Global Mesenchymal Stem Cell Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Mesenchymal Stem Cell Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Mesenchymal Stem Cell Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Mesenchymal Stem Cell Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Mesenchymal Stem Cell Drugs Company Ranking (2024-2026)
  6. 3.6 Global Mesenchymal Stem Cell Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Mesenchymal Stem Cell Drugs Company Product Type and Application
  8. 3.8 Global Mesenchymal Stem Cell Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mesenchymal Stem Cell Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mesenchymal Stem Cell Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mesenchymal Stem Cell Drugs Market by Type
  1. 4.1 Mesenchymal Stem Cell Drugs Type Introduction
  2. 4.1.1 Autologous Source
  3. 4.1.2 Allogeneic Source
  4. 4.2 Global Mesenchymal Stem Cell Drugs Sales Volume by Type
  5. 4.2.1 Global Mesenchymal Stem Cell Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mesenchymal Stem Cell Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Mesenchymal Stem Cell Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Mesenchymal Stem Cell Drugs Sales Value by Type
  9. 4.3.1 Global Mesenchymal Stem Cell Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Mesenchymal Stem Cell Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Mesenchymal Stem Cell Drugs Sales Value Share by Type (2021-2032)
5 Mesenchymal Stem Cell Drugs Market by Application
  1. 5.1 Mesenchymal Stem Cell Drugs Application Introduction
  2. 5.1.1 Tissue Repair
  3. 5.1.2 Immunomodulation
  4. 5.2 Global Mesenchymal Stem Cell Drugs Sales Volume by Application
  5. 5.2.1 Global Mesenchymal Stem Cell Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Mesenchymal Stem Cell Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Mesenchymal Stem Cell Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Mesenchymal Stem Cell Drugs Sales Value by Application
  9. 5.3.1 Global Mesenchymal Stem Cell Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Mesenchymal Stem Cell Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Mesenchymal Stem Cell Drugs Sales Value Share by Application (2021-2032)
6 Mesenchymal Stem Cell Drugs Regional Sales and Value Analysis
  1. 6.1 Global Mesenchymal Stem Cell Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mesenchymal Stem Cell Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Mesenchymal Stem Cell Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Mesenchymal Stem Cell Drugs Sales by Region (2027-2032)
  5. 6.3 Global Mesenchymal Stem Cell Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mesenchymal Stem Cell Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mesenchymal Stem Cell Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mesenchymal Stem Cell Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Mesenchymal Stem Cell Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Mesenchymal Stem Cell Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Mesenchymal Stem Cell Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mesenchymal Stem Cell Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Mesenchymal Stem Cell Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mesenchymal Stem Cell Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mesenchymal Stem Cell Drugs Sales Value Share by Country, 2025 VS 2032
7 Mesenchymal Stem Cell Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Mesenchymal Stem Cell Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mesenchymal Stem Cell Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Mesenchymal Stem Cell Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Mesenchymal Stem Cell Drugs Sales by Country (2027-2032)
  6. 7.4 Global Mesenchymal Stem Cell Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mesenchymal Stem Cell Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mesenchymal Stem Cell Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mesenchymal Stem Cell Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mesenchymal Stem Cell Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mesenchymal Stem Cell Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Anterogen
  2. 8.1.1 Anterogen Company Information
  3. 8.1.2 Anterogen Business Overview
  4. 8.1.3 Anterogen Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Anterogen Mesenchymal Stem Cell Drugs Product Portfolio
  6. 8.1.5 Anterogen Recent Developments
  7. 8.2 JCR Pharmaceuticals
  8. 8.2.1 JCR Pharmaceuticals Company Information
  9. 8.2.2 JCR Pharmaceuticals Business Overview
  10. 8.2.3 JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Product Portfolio
  12. 8.2.5 JCR Pharmaceuticals Recent Developments
  13. 8.3 Medipost
  14. 8.3.1 Medipost Company Information
  15. 8.3.2 Medipost Business Overview
  16. 8.3.3 Medipost Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Medipost Mesenchymal Stem Cell Drugs Product Portfolio
  18. 8.3.5 Medipost Recent Developments
  19. 8.4 Pharmicell
  20. 8.4.1 Pharmicell Company Information
  21. 8.4.2 Pharmicell Business Overview
  22. 8.4.3 Pharmicell Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pharmicell Mesenchymal Stem Cell Drugs Product Portfolio
  24. 8.4.5 Pharmicell Recent Developments
  25. 8.5 Stempeutics
  26. 8.5.1 Stempeutics Company Information
  27. 8.5.2 Stempeutics Business Overview
  28. 8.5.3 Stempeutics Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Stempeutics Mesenchymal Stem Cell Drugs Product Portfolio
  30. 8.5.5 Stempeutics Recent Developments
  31. 8.6 Osiris Therapeutics
  32. 8.6.1 Osiris Therapeutics Company Information
  33. 8.6.2 Osiris Therapeutics Business Overview
  34. 8.6.3 Osiris Therapeutics Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Osiris Therapeutics Mesenchymal Stem Cell Drugs Product Portfolio
  36. 8.6.5 Osiris Therapeutics Recent Developments
  37. 8.7 CHIESI Farmaceutici
  38. 8.7.1 CHIESI Farmaceutici Company Information
  39. 8.7.2 CHIESI Farmaceutici Business Overview
  40. 8.7.3 CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Product Portfolio
  42. 8.7.5 CHIESI Farmaceutici Recent Developments
  43. 8.8 Takeda
  44. 8.8.1 Takeda Company Information
  45. 8.8.2 Takeda Business Overview
  46. 8.8.3 Takeda Mesenchymal Stem Cell Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Takeda Mesenchymal Stem Cell Drugs Product Portfolio
  48. 8.8.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mesenchymal Stem Cell Drugs Value Chain Analysis
  2. 9.1.1 Mesenchymal Stem Cell Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mesenchymal Stem Cell Drugs Sales Mode & Process
  6. 9.2 Mesenchymal Stem Cell Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mesenchymal Stem Cell Drugs Distributors
  9. 9.2.3 Mesenchymal Stem Cell Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst